Some people report subjective changes, while others feel no benefit or experience nausea, pressure, cramping, headache, dizziness, or fatigue
Indications and Limitations of Use Victoza (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease
Currently, the mainstream obesity treatment using GLP-1 analogs is subcutaneous injection. The most common products are injections once a day or once a week, and they must be refrigerated
At Centra Internal Medicine, we follow evidence-based guidelines that recommend patients continue tirzepatide as long as they are experiencing benefitssuch as ongoing weight loss or improved overall metabolic healthand are not experiencing intolerable side effects
The math behind accumulation For the mathematically curious, here is what the plotter calculates
Heres where semaglutide shines: A 2025 meta-analysis (a birds eye examination of existing literature on a given topic) concluded GLP-1s could significantly reduce the prevalence of sleep apnea due to their research showing a threefold decrease in AHI, the medical metric used to measure how disruptive sleep apnea is on rest
